Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Tiotropium bromide

First Posted Date: 2011-06-28

Last Posted Date: 2015-04-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 101

Registration Number: NCT01383499

Locations: 🇩🇪
205.425.49005 Boehringer Ingelheim Investigational Site, Bochum, Germany
🇩🇪
205.425.49004 Boehringer Ingelheim Investigational Site, Dresden, Germany
🇭🇺
205.425.36002 Boehringer Ingelheim Investigational Site, Mosdos, Hungary

and more 21 locations

Phase I Study of AbGn-168H in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: AbGn-168H

First Posted Date: 2011-06-22

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT01378364

Locations: 🇩🇪
1304.1.4901 Boehringer Ingelheim Investigational Site, Berlin, Germany

Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: BI 201335
Drug: Darunavir
Drug: Ritonavir

First Posted Date: 2011-06-16

Last Posted Date: 2015-07-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT01374802

Locations: 🇩🇪
1220.49.1 Boehringer Ingelheim Investigational Site, Berlin, Germany

Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: low dose
Drug: normal dose

First Posted Date: 2011-06-10

Last Posted Date: 2015-08-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 29

Registration Number: NCT01371006

Locations: 🇨🇭
1220.20.41001 Boehringer Ingelheim Investigational Site, Basel, Switzerland

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Hypertension

Interventions: Drug: Placebo
Drug: BI 10773

First Posted Date: 2011-06-09

Last Posted Date: 2016-02-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 825

Registration Number: NCT01370005

Locations: 🇺🇸
1245.48.10012 Boehringer Ingelheim Investigational Site, Marietta, Georgia, United States
🇳🇱
1245.48.31017 Boehringer Ingelheim Investigational Site, Zoetermeer, Netherlands
🇺🇸
1245.48.10027 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States

and more 117 locations

Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 10773
Drug: Placebo (low dose)
Drug: Metformin
Drug: Placebo (high dose)

First Posted Date: 2011-06-07

Last Posted Date: 2014-06-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1162

Registration Number: NCT01368081

Locations: 🇯🇵
1245.52.033 Boehringer Ingelheim Investigational Site, Isehara, Kanagawa, Japan
🇯🇵
1245.52.052 Boehringer Ingelheim Investigational Site, Kitakyushu, Fukuoka, Japan
🇯🇵
1245.52.073 Boehringer Ingelheim Investigational Site, Chiyoda-ku, Tokyo, Japan

and more 84 locations

Ambroxol Spray Sore Throat Study

Phase 2

Completed

Conditions: Pharyngitis
Pain

Interventions: Drug: Ambroxol Spray
Drug: Placebo Spray

First Posted Date: 2011-05-27

Last Posted Date: 2014-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 494

Registration Number: NCT01361802

Locations: 🇿🇦
18.504.27015 Boehringer Ingelheim Investigational Site, Bloemfontein, South Africa
🇿🇦
18.504.27005 Boehringer Ingelheim Investigational Site, Cape Town, South Africa
🇿🇦
18.504.27011 Boehringer Ingelheim Investigational Site, Cape Town, South Africa

and more 12 locations

To Assess the Bioequivalence of Brotizolam Tablets 250 Mcg vs. Lendormin Tablets 250 Mcg Administered to Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lendormin tablet
Drug: Brotizolam tablet

First Posted Date: 2011-05-26

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT01361022

Locations: 🇨🇳
263.511.1 Boehringer Ingelheim Investigational Site, Taipei, Taiwan

a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

Completed

Conditions: Parkinson Disease

Interventions: Drug: pramipexole

First Posted Date: 2011-05-26

Last Posted Date: 2014-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2017

Registration Number: NCT01361009

Locations: 🇨🇳
Boehringer Ingelheim Investigational Site 52, Suzhou, China
🇨🇳
Boehringer Ingelheim Investigational Site 57, Beijing, China
🇨🇳
Boehringer Ingelheim Investigational Site 60, Beijing, China

and more 100 locations

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Phase 3

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: BI 201335
Drug: Pegylated Interferon-alpha (IFN)
Drug: Ribavirin (RBV)
Drug: Placebo

First Posted Date: 2011-05-24

Last Posted Date: 2016-08-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 678

Registration Number: NCT01358864

Locations: 🇺🇸
1220.7.0085 Boehringer Ingelheim Investigational Site, Baton Rouge, Louisiana, United States
🇺🇸
1220.7.0087 Boehringer Ingelheim Investigational Site, Baton Rouge, Louisiana, United States
🇨🇦
1220.7.1006 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada

and more 113 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy